CES Innovation Award given to Heru for wearable diagnostic solution

Article

The company’s re:Vive technology features 6 vision diagnostic exams, supported by 5 reimbursable CPT codes in 1 wearable solution.

CES Innovation Award given to Heru for wearable diagnostic solution

Heru Inc. has been named a CES 2022 Innovation Awards Honoree in the Virtual and Augmented Reality category for re:Vive, the company’s multi-modal, wearable diagnostic solution used to screen and diagnose visual defects.

The announcement was made ahead of CES 2022 technology conference, which will be held January 5-8, 2022, in Las Vegas.

“On behalf of eye care professionals around the world working to preserve eyesight, we are honored to receive such a prestigious award,” said Mohamed Abou Shousha, MD, PhD, Heru’s founder and CEO. “re:Vive by Heru improves access to vision care and provides physicians with a single, space-saving diagnostic, health and wellness tool which has revolutionized how screening and diagnosis for visual defects is performed in eye care.”

Heru developed its re:Vive platform in partnership with the University of Miami’s Bascom Palmer Eye Institute, the U.S.’s leading eye hospital. The platform features patented vision diagnostics software on commercially available AR/VR head-mounted displays. CES selected Heru’s innovative technology from a record number of submissions—more than 1800—to be recognized with this year’s Innovation Award.

“Globally, approximately 450 million people are affected by visual defects caused by strokes, glaucoma, age-related macular degeneration and other disorders,” Maurice R. Ferré, MD, CEO, Insightec and chairman of Heru’s Board of Directors, said in a statement. “Yet the decades-old standard of care is immobile, bulky, expensive, and requires a skilled technician or clinician to operate, limiting patients’ access to care. Limited access means that millions of individuals suffering from visual defects remain undiagnosed, causing irreversible damage to their eyesight. Heru’s technology brings us into an era in healthcare where improved access is no longer a goal, it is the new reality.”

Heru recently announced the expansion of their diagnostic platform to include three new testing modalities which enable physicians to perform 6 vision diagnostic, health and wellness exams, supported with 5 reimbursable CPT codes, in 1 wearable solution. The expanded platform transforms the diagnostic landscape, eliminating several legacy devices while providing physicians with additional avenues for reimbursement to build practice revenue.

“Heru’s award-winning technology enables diagnostic exams to seamlessly be performed anywhere, even in remote locations, with clinical results available in real-time, providing the potential to expand screening beyond traditional eye care practices and points of care," Kerri-Lynn Primmer Morris, Microsoft’s Chief Technology Officer, Healthcare, U.S. Enterprises, and member of Heru’s Board of Directors, said in a statement.

According to the company, once patients slip on the portable, lightweight headset, the exams are guided by Heru’s onboard virtual “personality,” which creates an enjoyable, personal experience that teaches, encourages, and supports the patient throughout the process. This frees up technicians and clinicians during the examination so they can tend to their practice, interpret clinical data and educate patients on their treatment options.

“Screening for visual defects is only the beginning,” sFrederic H. Moll, MD, Chief Development Officer, Johnson & Johnson Robotics, Heru advisor and investor, said in a statement. “In clinical development are therapeutic applications which include augmented vision correction. This new, cutting-edge technology will be the first of its kind and will transform the lives of patients with compromised vision around the world.”

Owned and produced by the Consumer Technology Association (CTA), the CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. A panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design.

Related Content: Interview with Heru's Founder & CEO | Ophthalmology | Conference Coverage

Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.